When Erythrocytosis on Testosterone Cypionate Becomes a Reason to Stop

What hematocrit level does the guidance name?

A 2023 clinical consultation guide in European Urology Focus says providers should decrease or discontinue testosterone therapy if hematocrit exceeds 54%, until it normalizes [1].

It is not a consensus rule. A 2025 systematic review of drug-induced erythrocytosis, covering 45 studies of which 35 were on testosterone or other androgens, concluded that there is no clear consensus among clinicians about how the condition should be diagnosed or managed [3]. A 2022 review went further, noting that the hematocrit cutoffs in several guidelines appear arbitrarily chosen and that evidence that testosterone-related erythrocytosis causes harm is scarce [4].

The Endocrine Society's 2018 guideline approaches it from the other end: it recommends against starting testosterone therapy in men with elevated hematocrit, and recommends monitoring hematocrit during the first year of treatment [2]. A 2014 Lancet review lists erythrocytosis among the contraindications to testosterone replacement [8].

Studies define erythrocytosis at lower levels than 54%: above 50% in a retrospective review [6] and above 52% (hematocrit 0.52) in a 2015 review [10].

How often does it happen on cypionate?

A retrospective review of 178 hypogonadal men treated with a single formulation and followed for three years found erythrocytosis (hematocrit above 50%) in 66.7% of the 57 men on injectable testosterone, 12.8% of the 47 on gels, and 35.1% of the 74 on pellets [6]. The injection group was younger (mean 42.5 versus about 54 years) and started with a higher baseline hematocrit, and the study was not randomized [6].

The 2025 systematic review reported erythrocytosis rates of up to 66.7% in men on prescription testosterone, with intramuscular formulations, higher doses and older age associated with increased risk [3]. The 2015 review reported that men on testosterone replacement had a 315% greater risk of erythrocytosis (hematocrit above 0.52) than controls [10].

How much do different formulations raise hematocrit?

The cypionate label's pharmacology section states that androgens stimulate red blood cell production by enhancing production of erythropoietic stimulation factor [7]. A 2018 review lists the mechanisms under study, including hepcidin, iron sequestration and turnover, erythropoietin production, bone marrow stimulation and genetic factors, and notes that short-acting injectable formulations carry the highest incidence of erythrocytosis [11].

In a network meta-analysis of 29 placebo-controlled randomized trials (3,393 men), mean hematocrit rose 4.0% with intramuscular testosterone enanthate or cypionate (95% CI 2.9 to 5.1), 3.0% with gel (1.8 to 4.3), 4.3% with oral testosterone undecanoate, 1.6% with intramuscular testosterone undecanoate, and 1.4% with patch, all versus placebo [5]. Only the difference between intramuscular enanthate or cypionate and patch reached significance; the other pairs were not significantly different from one another [5]. The 2015 review noted that all formulations raise hemoglobin and hematocrit, injectables the most [10].

What the Depo-Testosterone label says

The Depo-Testosterone label lists polycythemia among the hematologic adverse reactions of androgens, says hemoglobin and hematocrit should be checked periodically during long-term use, and notes that increased red blood cell mass may increase the risk of thromboembolic events [7].

Symptoms the label lists

The Depo-Testosterone label says patients reporting pain, edema, warmth and erythema in the lower extremity should be evaluated for deep vein thrombosis, and those with acute shortness of breath for pulmonary embolism; if a venous thromboembolic event is suspected, the label says to discontinue testosterone cypionate and begin appropriate workup [7].

Hematology reviews describe a role for hyperviscosity symptoms when considering phlebotomy or low-dose aspirin, on an individualized basis [9]. Whether a high hematocrit itself causes vascular events is unresolved: one review found limited evidence connecting the two [11], another called the erythrocytosis-VTE link inconclusive [10], and the 2025 systematic review reported thromboembolic events in up to 2.7% of men on testosterone therapy without establishing causation [3].

Other causes of erythrocytosis

Erythrocytosis has causes besides testosterone. Reviews of JAK2-unmutated erythrocytosis list relative or apparent polycythemia from volume contraction, hypoxia-driven causes such as cardiopulmonary disease and high altitude, and erythropoietin-producing tumors [12][9]. The step hematologists describe first is JAK2 mutation screening to exclude polycythemia vera [12][9].

Phlebotomy

A 2022 review describes dose adjustment, stopping therapy and phlebotomy as options for testosterone-related erythrocytosis [4]. For JAK2-unmutated erythrocytosis in general, which is not specific to testosterone, hematology guidance says phlebotomy should be considered for symptom control, cytoreductive therapy should be avoided, and low-dose aspirin and phlebotomy frequency may be individualized to symptom relief, cardiovascular comorbidity and thrombosis history [12][9]. One of these reviews notes that evidence-based treatment guidelines are lacking [9].